Munich/Germany – September 29, 2005: Definiens AG, a leader in advanced image intelligence solutions, today announced that ALTANA Pharma AG, a leading global pharmaceutical company, has selected Definiens Cellenger, an enterprise image analysis and understanding software, to enable the extraction of objects of interest from biomedical images.
By implementing Cellenger, ALTANA will be able to fully integrate its pharmaceutical information technology systems, providing preclinical scientists with direct access to data, which will result in rapid analysis, and quick, accurate reporting throughout their drug development process.
"The advantage of Definiens Cellenger is the recognition and separation of objects in images of heterogeneous structure in a self learning process." said Dr. Klaus Tuch, Head of Pathology at ALTANA Pharma." The quality of staining and image acquisition is less influencing the results. Dividing the process in three steps - selection of objects, manual correction and evaluation - is advantageous for repeated runs of different algorithms. For large sets of images the time could be reduced tremendously." adds Dr. Tuch.
"We are very pleased that ALTANA Pharma has chosen Definiens as their image analysis system of choice," said Thomas Heydler, chief executive officer of Definiens. "As one of the top 50 pharmaceutical companies in the world, ALTANA's selection of Definiens also demonstrates the acceptance of our technology beyond the first-adopter stage, and underscores the value that Definiens adds to the drug development process. We believe that this is an indication of the expanding market for our technology."
Definiens offers pharmaceutical companies high performance, reliable tools for image analysis, and a methodology that helps pharmaceutical companies maximize resources and speed decision-making during the drug development process.
| 
